Francois Maisonrouge is a Senior Managing Director in Evercore Partners’ advisory business with 31 years of relevant experience.

At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Medivation on its sale to Pfizer, AstraZeneca on the sale of its anti-infectives business to Pfizer, Shire on its acquisitions of Baxalta and Dyax, Shire on its defense across from Abbvie, AstraZeneca in its defense across from Pfizer, Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale to Fresenius, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck’s 50% stake in Merial, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer.

Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.

Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and a Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’Honneur.